Published in Antimicrob Agents Chemother on June 01, 1991
Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1995) 1.85
Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil. Antimicrob Agents Chemother (1996) 1.42
Inhibition of duck hepatitis B virus replication by 2',3'-dideoxy-3'-fluoroguanosine in vitro and in vivo. Antimicrob Agents Chemother (1996) 0.81
Strong and selective inhibitors of hepatitis B virus replication among novel N4-hydroxy- and 5-methyl-beta-L-deoxycytidine analogues. Antimicrob Agents Chemother (2007) 0.78
CONVERSION OF MONO- AND OLIGODEOXYRIBONUCLEOTIDES TO 5-TRIPHOSPHATES. J Am Chem Soc (1965) 59.91
Replication of the genome of a hepatitis B--like virus by reverse transcription of an RNA intermediate. Cell (1982) 16.71
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A (1986) 8.48
Human immunodeficiency virus reverse transcriptase. General properties and its interactions with nucleoside triphosphate analogs. J Biol Chem (1987) 1.94
In vitro and in vivo comparison of the abilities of purine and pyrimidine 2',3'-dideoxynucleosides to inhibit duck hepadnavirus. Antimicrob Agents Chemother (1989) 1.90
Effects of 2',3'-dideoxynucleosides on mammalian cells and viruses. J Cell Physiol (1984) 1.57
Inhibition of the replication of hepatitis B virus by the carbocyclic analogue of 2'-deoxyguanosine. Proc Natl Acad Sci U S A (1989) 1.54
An in vitro system for screening anti-hepatitis B virus drugs. Virology (1989) 1.44
Factors determining the activity of 2',3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. Mol Pharmacol (1988) 1.38
Inhibition of duck hepatitis B virus replication by 2',3'-dideoxycytidine. A potent inhibitor of reverse transcriptase. Gastroenterology (1989) 1.16
Potent inhibition of hepatitis B virus production in vitro by modified pyrimidine nucleosides. Antimicrob Agents Chemother (1990) 1.12
Inhibition of human and woodchuck hepatitis virus DNA polymerase by the triphosphates of acyclovir, 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine and E-5-(2-bromovinyl)-2'-deoxyuridine. Antiviral Res (1984) 1.07
Inhibition of HIV-associated reverse transcriptase by sugar-modified derivatives of thymidine 5'-triphosphate in comparison to cellular DNA polymerases alpha and beta. Biochem Biophys Res Commun (1987) 1.06
Inhibitory effects of 2'-fluorinated arabinosyl-pyrimidine nucleosides on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob Agents Chemother (1990) 1.06
Phosphorylation, anti-HIV activity and cytotoxicity of 3'-fluorothymidine. Biochem Biophys Res Commun (1988) 1.04
Antiviral strategies in chronic hepatitis B virus infection: II. Inhibition of duck hepatitis B virus in vitro using conventional antiviral agents and supercoiled-DNA active compounds. J Med Virol (1990) 0.99
Inhibition of hepatitis B virus DNA polymerase by 3'-fluorothymidine triphosphate and other modified nucleoside triphosphate analogs. J Med Virol (1990) 0.92
Inhibition of RNA- and DNA-dependent duck hepatitis B virus DNA polymerase activity by nucleoside and pyrophosphate analogs. Antiviral Res (1989) 0.88
Inhibition of HIV-replication by 3'-fluoro-modified nucleosides with low cytotoxicity. Biochem Biophys Res Commun (1989) 0.85
3'-Fluoro-2',3'-dideoxyribonucleoside 5'-triphosphates: terminators of DNA synthesis. FEBS Lett (1985) 0.84
Inhibition of hepatitis B virus DNA polymerase by 3'-azido-3'-deoxythymidine triphosphate but not by its threo analog. J Med Virol (1987) 0.80
Effect of 3'-azido-3'-deoxythymidine on replication of duck hepatitis B virus in vivo and in vitro. J Med Virol (1989) 0.79
Preliminary evidence that azidothymidine does not affect hepatitis B virus replication in acquired immunodeficiency syndrome (AIDS) patients. J Med Virol (1989) 0.78
Inhibition of human hepatitis B virus DNA polymerase and duck hepatitis B virus DNA polymerase by triphosphates of thymidine analogs and pharmacokinetic properties of the corresponding nucleosides. J Med Virol (1988) 0.78
Inhibition of HIV-1 reverse transcriptase by 5'-triphosphates of 5-substituted uridine analogs. Antiviral Res (1989) 0.77
A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol (1995) 3.35
Temporal creatine kinase curves in acute myocardial infarction. Implications of a good empiric fit with the log-normal function. Am J Clin Pathol (1993) 1.75
Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother (2009) 1.75
[The taxonomic problem of Clostridium sordellii and Clostridium bifermentans]. Med Dosw Mikrobiol (1966) 1.72
Indigenous hepatitis E virus infection of a plasma donor in Germany. Vox Sang (2009) 1.60
Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin (2008) 1.55
Recombination in Tula hantavirus evolution: analysis of genetic lineages from Slovakia. J Virol (1999) 1.54
Spatial and temporal trends and effects of contaminants in the Canadian Arctic marine ecosystem: a review. Sci Total Environ (1999) 1.53
Dobrava hantavirus causes hemorrhagic fever with renal syndrome in central Europe and is carried by two different Apodemus mice species. J Med Virol (2001) 1.42
[Expertise of current trends and future perspectives in rehabilitation research in Germany]. Rehabilitation (Stuttg) (2007) 1.41
Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation. Gut (2009) 1.40
Hypoxia-ischemia causes abnormalities in glutamate transporters and death of astroglia and neurons in newborn striatum. Ann Neurol (1997) 1.39
Amyloid disease of the heart. Clin Cardiol (1994) 1.37
Seroprevalence of hantavirus antibodies in Germany as determined by a new recombinant enzyme immunoassay. Eur J Clin Microbiol Infect Dis (1995) 1.28
Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract (2010) 1.25
Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther (2008) 1.23
Milk protein-derived peptide inhibitors of angiotensin-I-converting enzyme. Br J Nutr (2000) 1.22
Type, prevalence, and significance of core promoter/enhancer II mutations in hepatitis B viruses from immunosuppressed patients with severe liver disease. J Virol (1996) 1.21
Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus. Hepatology (1997) 1.20
Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus. J Virol (1997) 1.17
Core particles of hepatitis B virus as carrier for foreign epitopes. Adv Virus Res (1998) 1.17
Frequent and rapid emergence of mutated pre-C sequences in HBV from e-antigen positive carriers who seroconvert to anti-HBe during interferon treatment. Virology (1992) 1.15
Prevalence of markers for hepatitis A, B and C in the German population. Results of the German National Health Interview and Examination Survey 1998. Eur J Epidemiol (2001) 1.14
Potent inhibition of hepatitis B virus production in vitro by modified pyrimidine nucleosides. Antimicrob Agents Chemother (1990) 1.12
Short report: simultaneous occurrence of Dobrava, Puumala, and Tula Hantaviruses in Slovakia. Am J Trop Med Hyg (1999) 1.11
[The Bremen mortality index]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz (2004) 1.10
Depression, anxiety, post-traumatic stress disorder and health-related quality of life and its association with social support in ambulatory prostate cancer patients. Eur J Cancer Care (Engl) (2010) 1.10
The Hawthorne effect: can it be measured and utilized? Br J Anaesth (2013) 1.07
Validation of diabetes case definitions using administrative claims data. Diabet Med (2011) 1.06
Inhibition of HIV-associated reverse transcriptase by sugar-modified derivatives of thymidine 5'-triphosphate in comparison to cellular DNA polymerases alpha and beta. Biochem Biophys Res Commun (1987) 1.06
Human cytomegalovirus (HCMV) encephalitis in an immunocompetent young person and diagnostic reliability of HCMV DNA PCR using cerebrospinal fluid of nonimmunosuppressed patients. J Clin Microbiol (1998) 1.05
Phosphorylation, anti-HIV activity and cytotoxicity of 3'-fluorothymidine. Biochem Biophys Res Commun (1988) 1.04
Structured parent education in the management of childhood atopic dermatitis: the Berlin model. Patient Educ Couns (2000) 1.04
Clinical characterization of Dobrava hantavirus infections in Germany. Clin Nephrol (2001) 1.04
Test-ordering by multiple physicians increases unnecessary laboratory examinations. Arch Pathol Lab Med (1988) 1.02
Prophylaxis with povidone-iodine against induction of oral mucositis by radiochemotherapy. Support Care Cancer (1998) 1.02
Fatal outcome of lung transplantation in cystic fibrosis patients due to small-colony variants of the Burkholderia cepacia complex. Eur J Clin Microbiol Infect Dis (2003) 1.01
Serum osmolality and outcome in intensive care unit patients. Acta Anaesthesiol Scand (2006) 1.00
Povidone-iodine in antisepsis--state of the art. Dermatology (1997) 0.99
Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology (1999) 0.98
Electrocardiogram acquisition during MR examinations for patient monitoring and sequence triggering. Magn Reson Med (1994) 0.98
Intraoperative blood losses and transfusion requirements during adult liver transplantation remain difficult to predict. Can J Anaesth (2001) 0.97
Synthesis of substituted 5-fluoro-5,6-dihydropyrimidines. Nucleic Acids Res (1975) 0.96
Anti-inflammatory properties of a liposomal hydrogel with povidone-iodine (Repithel) for wound healing in vitro. Burns (2008) 0.96
Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain. Int J Clin Pract (2008) 0.95
Genetic characterization of a new hantavirus detected in Microtus arvalis from Slovakia. Virus Genes (1995) 0.95
Efficacy and safety of rituximab in a patient with active rheumatoid arthritis and chronic disseminated pulmonary aspergillosis and history of tuberculosis. Rheumatology (Oxford) (2008) 0.95
Accumulation and persistence of hepatitis B virus core gene deletion mutants in renal transplant patients are associated with end-stage liver disease. Hepatology (1996) 0.94
Virucidal activity and cytotoxicity of the liposomal formulation of povidone-iodine. Antiviral Res (2002) 0.94
Heterogeneity of hepatitis B virus C-gene sequences: implications for amplification and sequencing. J Hepatol (1993) 0.94
Identification of a novel angiotensin-I-converting enzyme inhibitory peptide corresponding to a tryptic fragment of bovine beta-lactoglobulin. FEBS Lett (1997) 0.94
AIDS-related progressive multifocal leukoencephalopathy in the era of HAART: report of two cases and review of the literature. AIDS Patient Care STDS (2005) 0.94
Life-threatening Dobrava hantavirus infection with unusually extended pulmonary involvement. Clin Nephrol (2004) 0.93
Molecular effects of povidone-iodine on relevant microorganisms: an electron-microscopic and biochemical study. Dermatology (1997) 0.93
Bioactive peptides derived from milk proteins. Structural, physiological and analytical aspects. Nahrung (1995) 0.93
Spatial and temporal trends of contaminants in Canadian Arctic freshwater and terrestrial ecosystems: a review. Sci Total Environ (1999) 0.92
Inhibition of hepatitis B virus DNA polymerase by 3'-fluorothymidine triphosphate and other modified nucleoside triphosphate analogs. J Med Virol (1990) 0.92
Continuous versus intermittent stochastic resonance whole body vibration and its effect on pelvic floor muscle activity. Neurourol Urodyn (2012) 0.92
NMR studies of DNA duplexes singly cross-linked by different synthetic linkers. Nucleic Acids Res (1995) 0.91
Nucleosides and nucleotides: natural bioactive substances in milk and colostrum. Br J Nutr (2000) 0.91
Chimaeric HBV core particles carrying a defined segment of Puumala hantavirus nucleocapsid protein evoke protective immunity in an animal model. Vaccine (1998) 0.90
Mapping of immunodominant B-cell epitopes and the human serum albumin-binding site in natural hepatitis B virus surface antigen of defined genosubtype. J Gen Virol (2000) 0.90
Detection of human hantavirus infections in Lithuania. Infection (2005) 0.90
Stimulation of human peripheral blood lymphocytes by bioactive peptides derived from bovine milk proteins. FEBS Lett (1996) 0.90
Dynamics of superhelical DNA studied by photon correlation spectroscopy. Biophys Chem (1986) 0.90
[Prevalence of hantavirus infections in Germany]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz (2004) 0.90
Preservation of isolated intestinal segments using the University of Wisconsin solution. Transplant Proc (1991) 0.89
Povidone-iodine to prevent mucositis in patients during antineoplastic radiochemotherapy. Dermatology (1997) 0.89
Efficacy and proarrhythmia of oral sotalol in pediatric patients. J Am Coll Cardiol (1995) 0.88
Coding strategy of the S and M genomic segments of a hantavirus representing a new subtype of the Puumala serotype. Arch Virol (1995) 0.88
Inhibition of hepatitis B virus production by modified 2',3'-dideoxy-thymidine and 2',3'-dideoxy-5-methylcytidine derivatives. In vitro and in vivo studies. Biochem Pharmacol (1992) 0.88
Mapping of B-cell epitopes in the nucleocapsid protein of Puumala hantavirus. Viral Immunol (2002) 0.88
Two-dimensional gel analysis of the proteome of lager brewing yeasts. Yeast (2000) 0.87
Evaluation of an infectious disease consultation programme in a German tertiary care hospital. Infection (2013) 0.87
Effects of cell surface ganglioside sialidase inhibition on growth control and differentiation of human neuroblastoma cells. Eur J Cell Biol (1997) 0.87
Rational use of diagnostic tools in hepatitis C. J Hepatol (1996) 0.87
Lactokinins: whey protein-derived ACE inhibitory peptides. Nahrung (1999) 0.86
Anti-inflammatory effects of cannabinoid CB(2) receptor activation in endotoxin-induced uveitis. Br J Pharmacol (2014) 0.86
The surgical treatment of noma. Plast Reconstr Surg (1991) 0.86
HBV core particles allow the insertion and surface exposure of the entire potentially protective region of Puumala hantavirus nucleocapsid protein. Biol Chem (1999) 0.86
New chimaeric hepatitis B virus core particles carrying hantavirus (serotype Puumala) epitopes: immunogenicity and protection against virus challenge. J Biotechnol (1999) 0.86
Transmission of GBV-C/HGV from drug-addicted mothers to their babies. J Hepatol (1997) 0.85
Sensitivity of human adenoviruses to different groups of chemical biocides. J Hosp Infect (2004) 0.85
Inhibition of HIV-replication by 3'-fluoro-modified nucleosides with low cytotoxicity. Biochem Biophys Res Commun (1989) 0.85
TNF-alpha and IL-1alpha induce apoptosis in subconfluent rat mesangial cells. Evidence for the involvement of hydrogen peroxide and lipid peroxidation as second messengers. Cytokine (2000) 0.85
Analysis of hepatitis B virus populations in an interferon-alpha-treated patient reveals predominant mutations in the C-gene and changing e-antigenicity. Virology (1998) 0.85
Hepatitis B virus genomes from long-term immunosuppressed virus carriers are modified by specific mutations in several regions. J Gen Virol (1999) 0.85
[Doctor-patient interaction: dealing with difficult situations]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz (2012) 0.85
Toll-like receptor 3 mediates expression of clusterin/apolipoprotein J in vascular smooth muscle cells stimulated with RNA released from necrotic cells. Exp Cell Res (2010) 0.85
Selectivity of DNA polymerases toward alpha and beta nucleotide substrates of D and L series. FEBS Lett (1994) 0.85
Causes of death in HIV-infected patients from the Cologne-Bonn cohort. Infection (2013) 0.84
Telomerase protein rather than its RNA is the target of phosphorothioate-modified oligonucleotides. Nucleic Acids Res (1999) 0.84
[Local therapy of grade IIa burns: efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment]. Unfallchirurg (2007) 0.84
Effects of Betaisodona on parameters of host defense. Dermatology (1997) 0.84
Antibodies directed to envelope proteins of hepatitis C virus outside of hypervariable region 1. Virology (1998) 0.83
Immunodominant B-cell domains of hepatitis C virus envelope proteins E1 and E2 identified during early and late time points of infection. J Hepatol (1999) 0.83
Effect of polyvinylpyrrolidone-iodine liposomal hydrogel on wound microcirculation in SKH1-hr hairless mice. Eur Surg Res (2006) 0.83